Rise of Stock Prices in Obesity Medication Market

The chapter explores the surge in stock prices of companies producing GLP-1 agonists, originally for diabetes but now utilized in weight loss and obesity treatment. Additionally, it delves into the trend of obtaining these drugs from compounding pharmacies at lower prices and the emerging competition in the market for obesity medications.